[
	{
		"assertion_id": 168, 
		"context": null, 
		"created_on": "02/04/21", 
		"description": "Administration of bevacizumab in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", 
		"disease": "Melanoma", 
		"favorable_prognosis": null, 
		"features": [
			168
		], 
		"last_updated": "2019-06-13", 
		"oncotree_code": "MEL", 
		"oncotree_term": "Melanoma", 
		"predictive_implication": "Preclinical", 
		"sources": [
			67
		], 
		"submitted_by": "breardon@broadinstitute.org", 
		"therapy_name": "Bevacizumab", 
		"therapy_resistance": null, 
		"therapy_sensitivity": true, 
		"therapy_strategy": "VEGF/VEGFR inhibition", 
		"therapy_type": "Targeted therapy", 
		"validated": true
	}
]